Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2019

Same author

Risankizumab: First Global Approval.

Drugs·2019

Same author

Ravulizumab: First Global Approval.

Drugs·2019

Same author

<i>Ginkgo biloba</i> extract EGb 761<sup>®</sup> in the symptomatic treatment of mild-to-moderate dementia: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018

Same author

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2018

Same author

Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.

Clinical drug investigation·2017

Search research articles

Related Experiment Video

Updated: May 21, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Mogamulizumab: first global approval.

Joshuan M Subramaniam¹, Glenn Whiteside, Kate McKeage

¹Adis RD Insight, Auckland, New Zealand.

|June 13, 2012

Summary

Mogamulizumab, a novel antibody targeting CCR4, has gained approval in Japan for adult T-cell leukemia-lymphoma. This marks a significant milestone for Potelligent® technology in treating hematological malignancies.

Area of Science:

Immunology
Oncology
Pharmacology

Background:

Mogamulizumab is a defucosylated, humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4).
It is developed using Kyowa Hakko Kirin's Potelligent® technology, enhancing antibody-dependent cellular cytotoxicity by reducing fucose content.
This technology aims to improve therapeutic efficacy in various hematological malignancies and other conditions.

Purpose of the Study:

To summarize the developmental milestones of intravenous mogamulizumab.
To highlight the regulatory approval in Japan for adult T-cell leukemia-lymphoma (ATL).
To outline ongoing clinical development for other hematological conditions and asthma.

Main Methods:

Review of development history and technological advancements.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: May 21, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Analysis of clinical trial phases and regulatory submissions.

Focus on the mechanism of action related to CCR4 targeting and antibody-dependent cellular cytotoxicity.

Main Results:

Mogamulizumab received marketing approval in Japan for relapsed or refractory adult T-cell leukemia-lymphoma (ATL).
It is the first approved antibody produced using Potelligent® technology.
Ongoing Phase II trials for ATL, cutaneous T-cell lymphoma, and peripheral T-cell lymphoma, plus a Phase I study for asthma.

Conclusions:

Mogamulizumab represents a significant advancement in antibody-based therapies for hematological malignancies.
The approval in Japan validates the efficacy and safety of Potelligent® technology.
Further clinical development is expected to expand its therapeutic applications.